Changes will give NHS patients ‘quicker access to new medicines’

The body said that its proposals, which are expected to be approved by its board on Wednesday, will make patient access to new treatments ‘fairer’.

Ella Pickover
Wednesday 19 January 2022 01:28
File photo dated 16/11/21 of the NHS logo (Dominic Lipinski/PA)
File photo dated 16/11/21 of the NHS logo (Dominic Lipinski/PA)

Changes to the way medicines and devices are assessed for NHS use in England will give patients “better access to life-changing medicines”, experts have said.

The National Institute for Health and Care Excellence (Nice) has proposed a raft of measures changing the way that it assesses new medicines and devices for NHS use.

The body said that its proposals, which are expected to be approved by its board on Wednesday, will make patient access to new treatments “fairer”.

If approved, Nice said that the measures would give patients quicker access to new treatments because those assessing them will have greater flexibility in decision making.

The changes being discussed will provide a robust foundation for our evaluations now and in the future and enable us to continue to lead the way in rapid, independent health technology assessments

Nice chief Professor Gillian Leng

Those making decisions about which treatments should be available on the NHS will also give greater weight to the lived experiences of patients.

Nice chief executive Professor Gillian Leng said: “Our vision at Nice is to be at the forefront of delivering access for patients in the NHS to valuable, evidence-based innovative medicines, medical devices and diagnostics.

“The changes being discussed will provide a robust foundation for our evaluations now and in the future and enable us to continue to lead the way in rapid, independent health technology assessments.”

Commenting on the reforms, Paul Catchpole from the Association of the British Pharmaceutical Industry said: “The changes set to be approved will help support better access to life-changing medicines.

“We share Nice’s ambition for fairness and equity of access to the latest medicines, including those for rare diseases.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in